KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Total Liabilities (2018 - 2025)

Historic Total Liabilities for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $223.4 million.

  • Vir Biotechnology's Total Liabilities fell 1330.36% to $223.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $223.4 million, marking a year-over-year decrease of 1330.36%. This contributed to the annual value of $248.4 million for FY2024, which is 2444.96% down from last year.
  • Vir Biotechnology's Total Liabilities amounted to $223.4 million in Q3 2025, which was down 1330.36% from $245.1 million recorded in Q2 2025.
  • Vir Biotechnology's Total Liabilities' 5-year high stood at $886.1 million during Q1 2022, with a 5-year trough of $223.4 million in Q3 2025.
  • In the last 5 years, Vir Biotechnology's Total Liabilities had a median value of $333.9 million in 2021 and averaged $422.8 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 40075.22% in 2021, then crashed by 6452.3% in 2024.
  • Over the past 5 years, Vir Biotechnology's Total Liabilities (Quarter) stood at $522.4 million in 2021, then skyrocketed by 38.61% to $724.1 million in 2022, then crashed by 54.59% to $328.8 million in 2023, then fell by 24.45% to $248.4 million in 2024, then dropped by 10.09% to $223.4 million in 2025.
  • Its Total Liabilities stands at $223.4 million for Q3 2025, versus $245.1 million for Q2 2025 and $263.9 million for Q1 2025.